<DOC>
	<DOCNO>NCT02786719</DOCNO>
	<brief_summary>Patients ask participate study patient diagnose high-risk neuroblastoma , common childhood cancer aggressive feature . If leave untreated , high-risk neuroblastoma fatal . Children high-risk neuroblastoma often respond current available treatment , high risk cancer return . This study test safety give standard induction treatment high-risk neuroblastoma without one drug commonly use prevent side effect . Current treatment high-risk neuroblastoma include anti-cancer drug ( chemotherapy ) , surgery , radiation therapy high-dose chemotherapy hematopoietic stem cell rescue . Treatment take one year complete occur 3 phase : induction , consolidation , maintenance . This study limit induction phase treatment . Induction therapy include six chemotherapy drug give different combination every 3 week total 6 course . For past decade , induction chemotherapy follow drug call granulocyte colony stimulate factor ( G-CSF , filgrastim , peg-filgrastim , Neupogen , Neulasta ) prevent side effect chemotherapy . G-CSF routinely give patient high risk neuroblastoma chemotherapy stimulate white blood cell production shorten time period absolute neutrophil count ( ANC ) , type white blood cell , low chemotherapy . G-CSF known shorten period low ANC approximately 3 day . When ANC low , patient risk get bacterial infection . Recent lab experiment mice show neuroblastoma tumor cell may respond G-CSF grow faster metastasize ( spread part body ) . There clinical trial compare survival child high risk neuroblastoma without G-CSF . This clinical trial first step towards give induction chemotherapy less G-CSF . The goal study determine safe give induction chemotherapy child neuroblastoma without give G-CSF routinely .</brief_summary>
	<brief_title>A Study High Risk Induction Chemotherapy Neuroblastoma Without Prophylactic Administration Myeloid Growth Factors</brief_title>
	<detailed_description>Chemotherapy : CYCLE 1+2 : Topotecan cyclophosphamide Cycle 3+5 : Cisplatin Etoposide Cycle 4+6 : Vincristine , Cyclophosphamide Doxorubicin Stem cell collection : After third cycle chemotherapy , stem cell collect possible stem cell transplantation later date use apheresis . In order enough stem cell present blood , patient need receive daily G-CSF injection collection . Surgery : After 5th cycle chemotherapy , patient surgery remove much remain tumor possible . Growth factor support : Growth factor increase number white blood cell , G-CSF GM-CSF ( granulocyte-macrophage colony stimulate factor ) give routinely study . GM-CSF give patient serious bacterial infection delay administer chemotherapy low neutrophil count . All people enrol study receive GM-CSF prior surgical removal main tumor . All people enrol study also receive G-CSF prior patient stem cell collect . Optional survey : This research study include optional survey regard quality life study . This survey fill cycle 1 4 chemotherapy .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Age great 12 month le 18 year old diagnosis Newly diagnose neuroblastoma ganglioneuroblastoma verify histology and/or demonstration tumor cell bone marrow elevate urinary catecholamine metabolite Must meet criterion High Risk disease Patients International Neuroblastoma Staging System ( INSS ) stage 4 disease eligible following : MYCN gene amplification ( great fourfold increase MYCN signal compare reference signal ) , regardless age additional biologic feature , Age great 18 month ( great 547 day ) regardless biologic feature , Age 12 18 month ( 365 547 day ) follow unfavorable biologic feature ( unfavorable pathology and/or DNA index = 1 ) biologic feature indeterminate/unsatisfactory/unknown Patients INSS stage 3 disease eligible following : MYCN amplification , regardless age additional biologic feature , Age great 18 month ( great 547 day ) unfavorable pathology , regardless MYCN status Patients INSS stage 2a/2b MYCN amplification regardless age additional biologic feature Patients great equal 365 day initially diagnose INSS stage 1 2 progressed stage 4 without interval chemotherapy Patients may prior systemic therapy except : Localized emergency radiation sit life threaten functioning disease , No 1 cycle chemotherapy accord low intermediate risk regimens prior determination MYCN amplification histology , long patient DID NOT receive type granulocyte colony stimulate factor ( GCSF ) part therapy . Patients must adequate hematopoietic function define : Absolute neutrophil count ( ANC ) great equal 750/μL , Platelet count great equal 75,000/μL , The criterion meet patient bone marrow involvement tumor . Patients must adequate liver function define : Direct bilirubin less equal 1.5 mg/dL total bilirubin ≤ 1.5 mg/dL , aspartate aminotrasnferase ( AST ) alanine aminotransferase ( ALT ) less equal to10 x upper limit normal age Patients must adequate renal function define : Creatinine clearance ( CrCl ) radioisotope glomerular filtration rate ( GFR ) great equal 70 mL/min/.73 m2 OR A serum creatinine base age/gender . Patients must adequate cardiac function define : Shortening fraction great equal 27 % echocardiogram , Ejection fraction great equal 50 % radionuclide angiogram Patients meet inclusion criterion Patients pregnant lactating Patients receive GCSF since time diagnosis current disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Sargramostim</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Topotecan</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Dexrazoxane</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Etoposide</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Vincristine</keyword>
	<keyword>Mesna</keyword>
</DOC>